search
Back to results

Nexpowder to Prevent Delayed Bleeding After Endoscopic Resection (NEX-ENDOHS)

Primary Purpose

Gastro Intestinal Bleeding, Polyps

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
NEXPOWDER-ENDOHS
Sponsored by
Erasme University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Gastro Intestinal Bleeding

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age: ≥18 year of age at the time of informed consent, Patients must have given written informed consent, Subjects with documented lesions with indication of upper or lower endoscopic removal by ESD or EMR with high risk of delayed bleeding (+/-16%), namely: All patients under anticoagulation (vitamin K antagonist, direct anticoagulant, non-fractionated heparin or low molecular weight heparin) or anti-aggregating (P2Y12 receptor antagonists), Patients without anticoagulation or anti-aggregating with indication of duodenal EMR or ESD (if duodenal cold snare EMR: only under anticoagulant or P2Y12 receptor antagonist), Resection field of ESD or EMR is ≥ 20mm (same size restriction in case of endoscopic papillectomy). Exclusion Criteria: Resection bed <20mm, Subject currently enrolled in another interventional confounding research (no contra-indication for image or blood collection in another protocol), Incapacitated subjects, pregnant or lactating women.

Sites / Locations

  • AZ Maria MiddelaresRecruiting
  • UZ Gasthuisberg (KUL)Recruiting
  • AZ Sint-Jan Brugge-OostendeRecruiting
  • AZ Delta Campus RumbekeRecruiting
  • HUB - Hôpital Erasme, Service de Gastro-Entérologie (ULB)Recruiting
  • Cliniques universitaires Saint-Luc (UCL)Recruiting
  • CHU Saint-PierreRecruiting
  • UZ GentRecruiting
  • Groupe Santé CHC - Clinique du MontLégiaRecruiting
  • Amsterdam UMC - Location VUMC
  • Amsterdam UMC - Location AMC
  • UMC Utrecht

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

NEXPOWDER-ENDOHS

Arm Description

Standard of care ESD or EMR procedure and application of Nexpowder on the resection site to prevent delayed bleeding.

Outcomes

Primary Outcome Measures

Safety in terms of Adverse Events (AE related to Nexpowder)
number of intraprocedural complications (perforation,…) number of post-procedure complications (delayed perforation, peritonitis,..)
Efficacy of Nexpowder in changing the delayed bleeding rate
Decrease the delayed bleeding rate

Secondary Outcome Measures

Full Information

First Posted
October 10, 2023
Last Updated
October 20, 2023
Sponsor
Erasme University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT06096948
Brief Title
Nexpowder to Prevent Delayed Bleeding After Endoscopic Resection
Acronym
NEX-ENDOHS
Official Title
Safety and Efficacy of a New Hemostatic System to Prevent Delayed Bleeding After Endoscopic Resection in a Selected High-risk Population
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 15, 2023 (Actual)
Primary Completion Date
April 30, 2024 (Anticipated)
Study Completion Date
July 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Erasme University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
Safety and effectiveness of a new hemostatic system to prevent delayed bleeding after endoscopic resection in a selected high-risk population (NEXPOWDER- ENDOHS). Indication: Patients with indication of endoscopy resection by endoscopic mucal resection (EMR) or endoscopic submucosal dissection (ESD) with high risk of delayed bleeding (≥5%). Hypotheses: The use of NexpowderTM after upper and lower gastrointestinal ESD or EMR of ≥20mm in high-risk population will prevent and decrease delayed bleeding to less than 5%.
Detailed Description
Hypotheses: The use of NexpowderTM after upper and lower gastrointestinal ESD or EMR of ≥20mm in high-risk population will prevent and decrease delayed bleeding to less than 5%. Study design: This is an investigator-initiated, multicentric, international, open-label, non-controlled, prospective study: All subjects with indications undergo screening and baseline visit, Informed consent is obtained when scheduling the ESD or EMR procedure, ESD or EMR is performed, at the end of resection, NexpowderTM is applied on the resected field, A follow up visit is scheduled at 4 weeks. Endpoints: Primary: Assess the delayed bleeding rate after ESD or EMR of ≥20mm in a selected high-risk population when using NexpowderTM at the end of the procedure. This hypothesis is that the use of NexpowderTM will reduce the rate of DB from 16% (reported rate in the literature) to less than 5% (excepted observed rate during the study). Secondary: Safety of NexpowderTM endoscopic hemostasis system, Procedure duration and NexpowderTM spaying duration, Length of stay in hospital, Post intervention pain, Adverse events related to the use of NexpowderTM: Per procedural Early (up to controlled endoscopy or at 24hours post procedure) Late (up to 4 weeks follow-up).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastro Intestinal Bleeding, Polyps

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
NEXPOWDER-ENDOHS
Arm Type
Experimental
Arm Description
Standard of care ESD or EMR procedure and application of Nexpowder on the resection site to prevent delayed bleeding.
Intervention Type
Device
Intervention Name(s)
NEXPOWDER-ENDOHS
Intervention Description
Standard of care ESD or EMR procedure and application of Nexpowder on the resection site to prevent delayed bleeding.
Primary Outcome Measure Information:
Title
Safety in terms of Adverse Events (AE related to Nexpowder)
Description
number of intraprocedural complications (perforation,…) number of post-procedure complications (delayed perforation, peritonitis,..)
Time Frame
1 month
Title
Efficacy of Nexpowder in changing the delayed bleeding rate
Description
Decrease the delayed bleeding rate
Time Frame
1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age: ≥18 year of age at the time of informed consent, Patients must have given written informed consent, Subjects with documented lesions with indication of upper or lower endoscopic removal by ESD or EMR with high risk of delayed bleeding (+/-16%), namely: All patients under anticoagulation (vitamin K antagonist, direct anticoagulant, non-fractionated heparin or low molecular weight heparin) or anti-aggregating (P2Y12 receptor antagonists), Patients without anticoagulation or anti-aggregating with indication of duodenal EMR or ESD (if duodenal cold snare EMR: only under anticoagulant or P2Y12 receptor antagonist), Resection field of ESD or EMR is ≥ 20mm (same size restriction in case of endoscopic papillectomy). Exclusion Criteria: Resection bed <20mm, Subject currently enrolled in another interventional confounding research (no contra-indication for image or blood collection in another protocol), Incapacitated subjects, pregnant or lactating women.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Arnaud Lemmers
Phone
+3225556559
Email
arnaud.lemmers@hubruxelles.be
First Name & Middle Initial & Last Name or Official Title & Degree
Julia Chaves Rodriguez
Phone
+3225551779
Email
julia.chaves.rodriguez@ulb.be
Facility Information:
Facility Name
AZ Maria Middelares
City
Gent
State/Province
Oost-Vlaanderen
ZIP/Postal Code
9000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pieter Dewint, MD, PhD
Phone
+3292467141
Email
pieter.dewint@azmmsj.be
First Name & Middle Initial & Last Name & Degree
Margaux Vansteelant
Phone
+3292467145
Email
Margaux.Vansteelant@azmmsj.be
Facility Name
UZ Gasthuisberg (KUL)
City
Leuven
State/Province
Vlaams Brabant
ZIP/Postal Code
3000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Raf Bisschops, MD, PhD
Phone
+3216341946
Email
raf.bisschops@uzleuven.be
First Name & Middle Initial & Last Name & Degree
Chelsea Camps
Phone
+3216341946
Email
chelsea.camps@uzleuven.be
Facility Name
AZ Sint-Jan Brugge-Oostende
City
Brugge
State/Province
West-Vlaanderen
ZIP/Postal Code
8000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christophe Snauwaert
Phone
+3250452180
Email
christophe.snauwaert@azsintjan.be
First Name & Middle Initial & Last Name & Degree
Nathalie Backers
Phone
+3250452180
Email
nathalie.backers@azsintjan.be
Facility Name
AZ Delta Campus Rumbeke
City
Roeselare
State/Province
West-Vlaanderen
ZIP/Postal Code
8800
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dominiek De Wulf
Phone
+3251237172
Email
Dominiek.DeWulf@azdelta.be
First Name & Middle Initial & Last Name & Degree
Katleen Kerstens
Phone
+3251237172
Email
katleen.kerstens@azdelta.be
Facility Name
HUB - Hôpital Erasme, Service de Gastro-Entérologie (ULB)
City
Brussels
ZIP/Postal Code
1070
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arnaud Lemmers, MD,PhD
Phone
+3225556559
Email
arnaud.lemmers@erasme.ulb.ac.be
First Name & Middle Initial & Last Name & Degree
Julia Chaves Rodriguez, MD
Phone
+3225551779
Email
Julia.Chaves.Rodriguez@ulb.be
First Name & Middle Initial & Last Name & Degree
Arnaud Lemmers, MD,PhD
First Name & Middle Initial & Last Name & Degree
Jacques Devière, MD,PhD
First Name & Middle Initial & Last Name & Degree
Vincent Huberty, MD, PhD
First Name & Middle Initial & Last Name & Degree
Marianna Arvanitakis, MD, PhD
First Name & Middle Initial & Last Name & Degree
Michael Fernandez, MD, PhD
First Name & Middle Initial & Last Name & Degree
Sohaib Ouazzani, MD, PhD
First Name & Middle Initial & Last Name & Degree
Ana-Maria Bucalau, MD, PhD
First Name & Middle Initial & Last Name & Degree
Julia Chaves Rodriguez, MD
First Name & Middle Initial & Last Name & Degree
Pierre Eisendrath, MD, PhD
First Name & Middle Initial & Last Name & Degree
Mariana Figueiredo, MD
Facility Name
Cliniques universitaires Saint-Luc (UCL)
City
Brussels
ZIP/Postal Code
1200
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pierre Deprez, MD, PhD
Phone
+3227642849
Email
pdeprez@saintluc.uclouvain.be
Facility Name
CHU Saint-Pierre
City
Brussel
ZIP/Postal Code
1000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pierre Eisendrath, MD, PhD
Phone
+3225354856
Email
pierre.eisendrath@stpierre-bru.be
First Name & Middle Initial & Last Name & Degree
Katty Renard
Phone
+3225354856
Email
katty.renard@stpierre-bru.be
Facility Name
UZ Gent
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Tate, MD, PhD
Phone
+3293322300
Email
David.tate@uzgent.be
First Name & Middle Initial & Last Name & Degree
Karolien Haenebalcke
Phone
+3293322300
Email
Karolien.Haenebalcke@uzgent.be
Facility Name
Groupe Santé CHC - Clinique du MontLégia
City
Liège
ZIP/Postal Code
4000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Philippe Leclercq
Phone
+3243554211
Email
philippe.leclercq@chc.be
First Name & Middle Initial & Last Name & Degree
Alexandro Maniglia
Phone
+3243554211
Email
alexandro.maniglia@chc.be
Facility Name
Amsterdam UMC - Location VUMC
City
Amsterdam
ZIP/Postal Code
1081
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roos Pouw, MD
Email
r.e.pouw@amsterdamumc.nl
First Name & Middle Initial & Last Name & Degree
Jacques Bergman, MD
Facility Name
Amsterdam UMC - Location AMC
City
Amsterdam
ZIP/Postal Code
1105
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Barbara Bastiaansen, MD
Email
b.a.bastiaansen@amsterdamumc.nl
First Name & Middle Initial & Last Name & Degree
Evelien Dekker, MD
Facility Name
UMC Utrecht
City
Utrecht
ZIP/Postal Code
3584
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leon Moons
Email
L.M.G.Moons@umcutrecht.nl
First Name & Middle Initial & Last Name & Degree
Bas Weusten
Email
b.l.a.weusten@umcutrecht.nl

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Nexpowder to Prevent Delayed Bleeding After Endoscopic Resection

We'll reach out to this number within 24 hrs